Skip to main content
Erschienen in:

Open Access 06.03.2018 | main topic

Shaping the future of liver surgery

Implementation of experimental insights into liver regeneration

verfasst von: D. Pereyra, P. Starlinger, MD, PhD

Erschienen in: European Surgery | Ausgabe 3/2018

Summary

Background

While liver surgery has become a safe and feasible operation technique, the incidence of postoperative liver dysfunction still remains a central problem. Approximately 10% of patients undergoing liver resection were shown to develop liver dysfunction, which is associated with an increased risk of morbidity and mortality. Yet, to date there is no effective treatment option for postoperative liver dysfunction available. The development of postoperative liver dysfunction was linked to a disruption in the liver’s potential to regenerate. Thus, it is importance to elucidate the underlying mechanisms of liver regeneration and to find potential therapeutic targets for the treatment of patients with postoperative liver dysfunction.

Methods

A review of the literature was carried out.

Results

We report on potential future interventions for improvement of liver regeneration after surgical resection. Moreover, we evaluate the benefits and drawbacks of hepatic progenitor cell therapy and hematopoietic stem cell therapy. However, the most significant improvement seems to come from molecular targets. Indeed, von Willebrand factor and its pharmacologic manipulation are among the most promising therapeutic targets to date. Furthermore, using the example of platelet-based therapy, we stress the potentially adverse effects of treatments for postoperative liver dysfunction.

Conclusion

The present review reports on the newest advances in the field of regenerative science, but also underlines the need for more research in the field of postoperative liver regeneration, especially in regard to translational studies.
Abkürzungen
HPC
Hepatic progenitor cell
HSC
Hematopoietic stem cells
IP-5HT
Intra-platelet serotonin
LD
Liver dysfunction
vWF-Ag
von Willebrand factor antigen

Introduction

Today, liver resection represents a safe and feasible therapeutic option for the treatment of malignant and benign liver tumors [1, 2]. This is due to a continuous refinement of surgical strategies, starting from a simple left lobe resection in 1888 and evolving into an adjustable procedure with a high degree of personalization to the patients’ needs [3]. The former limitations of liver surgery, namely, bleeding at the site of resection, bilobar tumor growth, and multiple metastasis within the liver, could be overcome, which makes major resection of up to 75% of the livers initial volume a feasible and safe operation [4, 5]. Indeed, postoperative mortality is reported to affect no more than 2–8% of patients undergoing liver resection, with the latter percentage referring to high-risk patients who require complex resections [69]. Of note, this is also due to advances in perioperative management of patients undergoing liver resection. In addition, the preoperative optimization of patients needing extensive liver resection has improved, with the most prominent example being preoperative portal vein embolization [10]. This technique allows for major resection also in patients with an initial future liver remnant of less than 25%, as it triggers regeneration in the healthy liver parenchyma.
While mortality rates in this specific patient cohort are within acceptable ranges, postoperative morbidity and prolonged hospitalization, including the need for intensive care unit management and specific interventions, still remain an important concern. According to recent literature, the incidence of postoperative morbidity remains stable at 30–50% [6, 9]. Interestingly, postoperative complications have been associated with the development of liver dysfunction (LD) and delayed hepatic regeneration [11]. Indeed, a well-functioning liver regeneration after resection is believed to be the central determinant of clinical outcome [12]. Further, a well-functioning liver regeneration allows for multiple consecutive resections if needed (Fig. 1). However, if the regenerative capacity is impaired and a patient develops postoperative LD, the clinical consequences are inevitable because to date no therapeutic approach to support postoperative liver regeneration has been identified. The fact that more than 65% of patients with postoperative LD will develop major complications highlights the need for adequate treatment options to support postoperative liver regeneration [13]. In the present review, we aim to present an overview of the most promising experimental data regarding potential therapeutic targets to support liver regeneration in patients suffering from postoperative LD.

Hepatic progenitor cells and cellular therapy

The liver consists of a variety of different cell types that display a high degree of interaction and niche dependency. Beside the main parenchymal cells, which are hepatocytes, liver-specific endothelial cells, cholangiocytes, hepatic stellate cells, and stationary macrophages (i. e., Kupffer cells) are the most frequent cell types in the liver [14]. These cells all show a high level of differentiation and specialization, which is also visible when looking at the different functions they need to fulfil. Recently, oval cells have been described as a potential hepatic progenitor cell (HPC) niche [15]. Indeed, this cell type was shown to have the ability to give rise to both hepatocytes and cholangiocytes, which led to the hypothesis that oval cells might be relevant for liver regeneration after tissue damage. Moreover, inducible progenitors were shown to be crucial for liver regeneration, and inhibition of their activation in a mouse model led to impaired liver regeneration after partial hepatectomy [16]. Thus, activation of HPCs and enforcement of differentiation to mature hepatocytes might be a potential therapeutic target for induction of liver regeneration. Español-Suñer et al. were able to show that in vivo activation of oval cells can be performed via the PGI2 analogue iloprost [17]. Although the arising hepatocytes showed a typical behavior and were able to proliferate upon activating stimuli in vivo, these cells only contributed to 2.45% of the total hepatocytes. Further, Español-Suñer and coworkers did not observe a massive increase in oval cell activation after partial hepatectomy in mice.
Interestingly, HPCs were found to be regulated by, if not even derived from, hematopoietic stem cells (HSC). These cells share a large panel of surface markers [18]. Furthermore, Y chromosomes were detected in female patients’ hepatocytes after bone marrow transplantation from a male donor [19]. Thus, a plethora of experimental studies addressed the question of whether cellular therapy via HSCs might contribute to liver regeneration in different models [20]. In conclusion, the studies provide diverging results: While HSCs seemed to improve the outcome of mice after liver damage, this improvement could not consistently be traced back to the engraftment of HSCs [21]. In some studies, an engraftment was only observed for 4% of transplanted HSCs. Nevertheless, a compensatory proliferation of hepatocytes took place in mice treated with HSCs. Accordingly, the beneficial effects of HSC therapy were thought to be either dependent on their ability to scavenge and neutralize reactive oxygen species or due to paracrine effects on hepatocytes [22, 23].
Taken together, both HPCs and HSCs might have a beneficial effect on liver regeneration. However, the available data are not conclusive yet and translational data as well as prospective human trials are needed to clarify the clinical applicability of this kind of cellular therapy.

Molecular targets—von Willebrand factor

In the past few years, molecular targets became more innovative in the field of liver regeneration. This might be due to the increased interest in pathophysiologic processes taking place during the complex process of liver regeneration. However, while there are abundant data on rodent models and in vitro experiments, only few translational data have been obtained to date. In this context, we recently published a translational study focusing on von Willebrand factor antigen (vWF-Ag) during postoperative liver regeneration in humans [24]. VWF-Ag is known for its role in primary hemostasis, where it facilitates the accumulation of platelets and their binding to the sub-endothelial matrix [25]. It is stored both in granules of platelets and endothelial cells and can be released upon stimulation. Previously, vWF-Ag was proposed as a marker for portal hypertension and cirrhosis [26]. However, the role of vWF-Ag in patients undergoing liver resection has not been addressed before. While a large clinical study showed that patients with high preoperative levels of vWF-Ag had a significantly increased risk for development of postoperative LD, complications, and even mortality, we aimed to provide more insight into the pathophysiological involvement of vWF-Ag in liver regeneration. Interestingly, Kirschbaum et al. recently published experimental data on the role of vWF-Ag during liver regeneration in mice [27]. They showed the central importance of vWF-Ag-dependent platelet accumulation especially during the early period after induction of liver regeneration. Indeed, the significance of platelets and platelet stored factors for a well-functioning liver regeneration has previously been shown by our group as well as by other researchers [12, 28, 29]. Thus, we took a closer look at vWF-Ag secretion during the early phase of liver regeneration (i. e., the first 2 h after portal vein ligation) in the human setting. Astonishingly, our results precisely followed the experimental data by Kirschbaum et al. We were able to validate previous reports on platelet accumulation within the regenerating liver. Interestingly, we also observed an increase in vWF-Ag within no more than 2 h of induction of liver regeneration. Most importantly, this initial increase was only seen in patients who did not develop LD in the postoperative time course, while patients with LD were not able to substantially secrete vWF-Ag in the early phase of liver regeneration. This led to the hypothesis that an initial burst in vWF-Ag might be relevant for induction of platelet-mediated liver regeneration.
Overall, this study provides an example of how therapeutic targets in the field of liver regeneration can be identified (for a summary, refer to Fig. 2). Thinking one step further, these data would suggest a beneficial effect of pharmacologic manipulation of vWF-Ag secretion. Indeed, drugs inducing this effect, such as vasopressin analogues, are already part of clinical routine. Moreover, a study investigating the use of terlipressin in patients undergoing major liver resection is currently being conducted (ClinicalTrials.gov Identifier: NCT01921985). Thus, this intervention might be the first treatment option for patients suffering from postoperative LD and might concomitantly improve the overall outcome of patients undergoing liver resection.

Drawbacks from treatments

While several different targets to treat patients suffering from postoperative LD are being investigated, not all of them will ultimately find their way into clinical practice. This can either be due to a reduced effectiveness in the human setting, as might be the case for HPC/HSC-based therapy, or that potential adverse effects of the respective treatment need to be investigated. Indeed, we and others previously hypothesized a potential positive effect of platelet-based therapy on the outcome of liver regeneration [12, 28, 29]. Specifically, within a previous study we showed that patients with low preoperative levels of intra-platelet serotonin (IP-5HT) prior to the operation have a higher risk for development of postoperative LD [30]. Thus, a pharmacological elevation of IP-5HT seemed to be a reasonable treatment option in patients undergoing liver resection. However, 5HT was also proposed as a pro-proliferative molecule for various malignant diseases including all main tumor entities of the liver [3134]. Hence, we conducted a study with the aim to elucidate the influence of IP-5HT on the oncological outcome of patients undergoing liver resection [35]. Strikingly, patients with high preoperative levels of IP-5HT were found to suffer more frequently from early tumor recurrence within 1 year postoperatively. This study put a huge caveat on platelet-based therapy. The initially considered pharmacological manipulation might induce adverse effects and a potential intervention has to be investigated with caution. Likewise, not only 5HT, but also other platelet-contained factors were shown to interact with malignant cells and metastasis [36]. Further, these data question the beneficial effect of a proliferation-based approach for improvement of postoperative liver regeneration, as induction of proliferation in hepatocytes most likely also induces proliferation in remaining micro-metastases and circulating tumor cells.

Conclusion

Liver regeneration is a highly complex process. Yet, its understanding is of pivotal importance to improve the outcome of patients undergoing liver resection. While a multitude of potential therapeutic targets were established in the past (most important results are summarized in Table 1), only few have the potential to ultimately act as a promising therapy for patients suffering from postoperative LD. Hence, more research, especially in the translational field, is imperatively needed. However, future research should not focus exclusively on basic science, as artificial models often neglect important aspects of the multifactorial process of liver regeneration and cancer and thus might overestimate certain results.
Table 1
Summary of the results
Section
Examples
Results
Cell-based therapy
Hepatic progenitor cells
Hematopoietic stem cells
Good results in experimental models
Clinical application needs to be evaluated
Molecular targets
von Willebrand factor
Experimental evaluation showed good results
Translational data available
Pharmacologic intervention in humans currently under investigation
Drawbacks
Platelets/serotonin
Central for liver regeneration and thus a potential target for improvement of liver regeneration
However, also pro-proliferative for malignant cells and an association with early disease recurrence was shown

Conflict of interest

D. Pereyra and P. Starlinger declare that they have no competing interests.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Literatur
1.
Zurück zum Zitat Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, Wong J. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg. 1999;229:322–30.CrossRefPubMedPubMedCentral Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, Wong J. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg. 1999;229:322–30.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Belghiti J, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg. 2000;191:38–46.CrossRefPubMed Belghiti J, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg. 2000;191:38–46.CrossRefPubMed
3.
Zurück zum Zitat Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, Corvera C, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg. 2002;236:397–406. discussion 406–397.CrossRefPubMedPubMedCentral Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, Corvera C, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg. 2002;236:397–406. discussion 406–397.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Shoup M, Gonen M, D’Angelica M, Jarnagin WR, DeMatteo RP, Schwartz LH, Tuorto S, et al. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg. 2003;7:325–30.CrossRefPubMed Shoup M, Gonen M, D’Angelica M, Jarnagin WR, DeMatteo RP, Schwartz LH, Tuorto S, et al. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg. 2003;7:325–30.CrossRefPubMed
6.
Zurück zum Zitat Shubert CR, Habermann EB, Truty MJ, Thomsen KM, Kendrick ML, Nagorney DM. Defining perioperative risk after hepatectomy based on diagnosis and extent of resection. J Gastrointest Surg. 2014;18:1917–28.CrossRefPubMed Shubert CR, Habermann EB, Truty MJ, Thomsen KM, Kendrick ML, Nagorney DM. Defining perioperative risk after hepatectomy based on diagnosis and extent of resection. J Gastrointest Surg. 2014;18:1917–28.CrossRefPubMed
7.
Zurück zum Zitat Booth CM, Nanji S, Wei X, Mackillop WJ. Management and outcome of colorectal cancer liver metastases in elderly patients: a population-based study. JAMA Oncol. 2015;1:1111–9.CrossRefPubMed Booth CM, Nanji S, Wei X, Mackillop WJ. Management and outcome of colorectal cancer liver metastases in elderly patients: a population-based study. JAMA Oncol. 2015;1:1111–9.CrossRefPubMed
8.
Zurück zum Zitat Gilg S, Sparrelid E, Isaksson B, Lundell L, Nowak G, Stromberg C. Mortality-related risk factors and long-term survival after 4460 liver resections in Sweden – a population-based study. Langenbecks Arch Surg. 2017;402:105–13.CrossRefPubMed Gilg S, Sparrelid E, Isaksson B, Lundell L, Nowak G, Stromberg C. Mortality-related risk factors and long-term survival after 4460 liver resections in Sweden – a population-based study. Langenbecks Arch Surg. 2017;402:105–13.CrossRefPubMed
9.
Zurück zum Zitat Shubert CR, Habermann EB, Bergquist JR, Thiels CA, Thomsen KM, Kremers WK, Kendrick ML, et al. A NSQIP review of major morbidity and mortality of synchronous liver resection for colorectal metastasis stratified by extent of liver resection and type of Colorectal resection. J Gastrointest Surg. 2015;19:1982–94.CrossRefPubMed Shubert CR, Habermann EB, Bergquist JR, Thiels CA, Thomsen KM, Kremers WK, Kendrick ML, et al. A NSQIP review of major morbidity and mortality of synchronous liver resection for colorectal metastasis stratified by extent of liver resection and type of Colorectal resection. J Gastrointest Surg. 2015;19:1982–94.CrossRefPubMed
11.
Zurück zum Zitat Rahbari NN, Garden OJ, Padbury R, Brooke-Smith M, Crawford M, Adam R, Koch M, et al. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery. 2011;149:713–24.CrossRefPubMed Rahbari NN, Garden OJ, Padbury R, Brooke-Smith M, Crawford M, Adam R, Koch M, et al. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery. 2011;149:713–24.CrossRefPubMed
12.
Zurück zum Zitat Lesurtel M, Graf R, Aleil B, Walther DJ, Tian Y, Jochum W, Gachet C, et al. Platelet-derived serotonin mediates liver regeneration. Science. 2006;312:104–7.CrossRefPubMed Lesurtel M, Graf R, Aleil B, Walther DJ, Tian Y, Jochum W, Gachet C, et al. Platelet-derived serotonin mediates liver regeneration. Science. 2006;312:104–7.CrossRefPubMed
13.
Zurück zum Zitat Skrzypczyk C, Truant S, Duhamel A, Langlois C, Boleslawski E, Koriche D, Hebbar M, et al. Relevance of the ISGLS definition of posthepatectomy liver failure in early prediction of poor outcome after liver resection: study on 680 hepatectomies. Ann Surg. 2014;260:865–70. discussion 870.CrossRefPubMed Skrzypczyk C, Truant S, Duhamel A, Langlois C, Boleslawski E, Koriche D, Hebbar M, et al. Relevance of the ISGLS definition of posthepatectomy liver failure in early prediction of poor outcome after liver resection: study on 680 hepatectomies. Ann Surg. 2014;260:865–70. discussion 870.CrossRefPubMed
14.
15.
Zurück zum Zitat Spee B, Carpino G, Schotanus BA, Katoonizadeh A, Vander Borght S, Gaudio E, Roskams T. Characterisation of the liver progenitor cell niche in liver diseases: potential involvement of Wnt and Notch signalling. Gut. 2010;59:247–57.CrossRefPubMed Spee B, Carpino G, Schotanus BA, Katoonizadeh A, Vander Borght S, Gaudio E, Roskams T. Characterisation of the liver progenitor cell niche in liver diseases: potential involvement of Wnt and Notch signalling. Gut. 2010;59:247–57.CrossRefPubMed
16.
Zurück zum Zitat Karaca G, Swiderska-Syn M, Xie G, Syn WK, Kruger L, Machado MV, Garman K, et al. TWEAK/Fn14 signaling is required for liver regeneration after partial hepatectomy in mice. PLoS ONE. 2014;9:e83987.CrossRefPubMedPubMedCentral Karaca G, Swiderska-Syn M, Xie G, Syn WK, Kruger L, Machado MV, Garman K, et al. TWEAK/Fn14 signaling is required for liver regeneration after partial hepatectomy in mice. PLoS ONE. 2014;9:e83987.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Espanol-Suner R, Carpentier R, Van Hul N, Legry V, Achouri Y, Cordi S, Jacquemin P, et al. Liver progenitor cells yield functional hepatocytes in response to chronic liver injury in mice. Gastroenterology. 2012;143(e1567):1564–1575.e7.CrossRefPubMed Espanol-Suner R, Carpentier R, Van Hul N, Legry V, Achouri Y, Cordi S, Jacquemin P, et al. Liver progenitor cells yield functional hepatocytes in response to chronic liver injury in mice. Gastroenterology. 2012;143(e1567):1564–1575.e7.CrossRefPubMed
18.
Zurück zum Zitat Petersen BE, Grossbard B, Hatch H, Pi L, Deng J, Scott EW. Mouse A6-positive hepatic oval cells also express several hematopoietic stem cell markers. Hepatology. 2003;37:632–40.CrossRefPubMed Petersen BE, Grossbard B, Hatch H, Pi L, Deng J, Scott EW. Mouse A6-positive hepatic oval cells also express several hematopoietic stem cell markers. Hepatology. 2003;37:632–40.CrossRefPubMed
19.
Zurück zum Zitat Alison MR, Poulsom R, Jeffery R, Dhillon AP, Quaglia A, Jacob J, Novelli M, et al. Hepatocytes from non-hepatic adult stem cells. Nature. 2000;406:257.CrossRefPubMed Alison MR, Poulsom R, Jeffery R, Dhillon AP, Quaglia A, Jacob J, Novelli M, et al. Hepatocytes from non-hepatic adult stem cells. Nature. 2000;406:257.CrossRefPubMed
20.
Zurück zum Zitat Katoonizadeh A, Poustchi H, Malekzadeh R. Hepatic progenitor cells in liver regeneration: current advances and clinical perspectives. Liver Int. 2014;34:1464–72.CrossRefPubMed Katoonizadeh A, Poustchi H, Malekzadeh R. Hepatic progenitor cells in liver regeneration: current advances and clinical perspectives. Liver Int. 2014;34:1464–72.CrossRefPubMed
21.
Zurück zum Zitat Vassilopoulos G, Wang PR, Russell DW. Transplanted bone marrow regenerates liver by cell fusion. Nature. 2003;422:901–4.CrossRefPubMed Vassilopoulos G, Wang PR, Russell DW. Transplanted bone marrow regenerates liver by cell fusion. Nature. 2003;422:901–4.CrossRefPubMed
22.
Zurück zum Zitat Parekkadan B, van Poll D, Megeed Z, Kobayashi N, Tilles AW, Berthiaume F, Yarmush ML. Immunomodulation of activated hepatic stellate cells by mesenchymal stem cells. Biochem Biophys Res Commun. 2007;363:247–52.CrossRefPubMedPubMedCentral Parekkadan B, van Poll D, Megeed Z, Kobayashi N, Tilles AW, Berthiaume F, Yarmush ML. Immunomodulation of activated hepatic stellate cells by mesenchymal stem cells. Biochem Biophys Res Commun. 2007;363:247–52.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Kuo TK, Hung SP, Chuang CH, Chen CT, Shih YR, Fang SC, Yang VW, et al. Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology. 2008;134:2111–2121, 2121.e1-3.CrossRefPubMedPubMedCentral Kuo TK, Hung SP, Chuang CH, Chen CT, Shih YR, Fang SC, Yang VW, et al. Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology. 2008;134:2111–2121, 2121.e1-3.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Starlinger P, Pereyra D, Haegele S, Braeuer P, Oehlberger L, Primavesi F, Kohler A, et al. Perioperative von Willebrand factor dynamics are associated with liver regeneration and predict outcome after liver resection. Hepatology. 2017; https://doi.org/10.1002/hep.29651.CrossRef Starlinger P, Pereyra D, Haegele S, Braeuer P, Oehlberger L, Primavesi F, Kohler A, et al. Perioperative von Willebrand factor dynamics are associated with liver regeneration and predict outcome after liver resection. Hepatology. 2017; https://​doi.​org/​10.​1002/​hep.​29651.CrossRef
25.
Zurück zum Zitat Kanaji S, Fahs SA, Shi Q, Haberichter SL, Montgomery RR. Contribution of platelet vs. endothelial VWF to platelet adhesion and hemostasis. J Thromb Haemost. 2012;10:1646–52.CrossRefPubMedPubMedCentral Kanaji S, Fahs SA, Shi Q, Haberichter SL, Montgomery RR. Contribution of platelet vs. endothelial VWF to platelet adhesion and hemostasis. J Thromb Haemost. 2012;10:1646–52.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat La Mura V, Reverter JC, Flores-Arroyo A, Raffa S, Reverter E, Seijo S, Abraldes JG, et al. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. Gut. 2011;60:1133–8.CrossRefPubMed La Mura V, Reverter JC, Flores-Arroyo A, Raffa S, Reverter E, Seijo S, Abraldes JG, et al. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. Gut. 2011;60:1133–8.CrossRefPubMed
27.
Zurück zum Zitat Kirschbaum M, Jenne CN, Veldhuis ZJ, Sjollema KA, Lenting PJ, Giepmans BNG, Porte RJ, et al. Transient von Willebrand factor-mediated platelet influx stimulates liver regeneration after partial hepatectomy in mice. Liver Int. 2017;37:1731–7.CrossRefPubMed Kirschbaum M, Jenne CN, Veldhuis ZJ, Sjollema KA, Lenting PJ, Giepmans BNG, Porte RJ, et al. Transient von Willebrand factor-mediated platelet influx stimulates liver regeneration after partial hepatectomy in mice. Liver Int. 2017;37:1731–7.CrossRefPubMed
28.
Zurück zum Zitat Starlinger P, Alidzanovic L, Schauer D, Brugger P, Sommerfeldt S, Kuehrer I, Schoppmann SF, et al. Platelet-stored angiogenesis factors: clinical monitoring is prone to artifacts. Dis Markers. 2011;31:55–65.CrossRefPubMedPubMedCentral Starlinger P, Alidzanovic L, Schauer D, Brugger P, Sommerfeldt S, Kuehrer I, Schoppmann SF, et al. Platelet-stored angiogenesis factors: clinical monitoring is prone to artifacts. Dis Markers. 2011;31:55–65.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Starlinger P, Assinger A, Haegele S, Wanek D, Zikeli S, Schauer D, Birner P, et al. Evidence for serotonin as a relevant inducer of liver regeneration after liver resection in humans. Hepatology. 2014;60:257–66.CrossRefPubMed Starlinger P, Assinger A, Haegele S, Wanek D, Zikeli S, Schauer D, Birner P, et al. Evidence for serotonin as a relevant inducer of liver regeneration after liver resection in humans. Hepatology. 2014;60:257–66.CrossRefPubMed
31.
Zurück zum Zitat Alpini G, Invernizzi P, Gaudio E, Venter J, Kopriva S, Bernuzzi F, Onori P, et al. Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth. Cancer Res. 2008;68:9184–93.CrossRefPubMedPubMedCentral Alpini G, Invernizzi P, Gaudio E, Venter J, Kopriva S, Bernuzzi F, Onori P, et al. Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth. Cancer Res. 2008;68:9184–93.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Asada M, Ebihara S, Yamanda S, Niu K, Okazaki T, Sora I, Arai H. Depletion of serotonin and selective inhibition of 2B receptor suppressed tumor angiogenesis by inhibiting endothelial nitric oxide synthase and extracellular signal-regulated kinase 1/2 phosphorylation. Neoplasia. 2009;11:408–17.CrossRefPubMedPubMedCentral Asada M, Ebihara S, Yamanda S, Niu K, Okazaki T, Sora I, Arai H. Depletion of serotonin and selective inhibition of 2B receptor suppressed tumor angiogenesis by inhibiting endothelial nitric oxide synthase and extracellular signal-regulated kinase 1/2 phosphorylation. Neoplasia. 2009;11:408–17.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Gurbuz N, Ashour AA, Alpay SN, Ozpolat B. Down-regulation of 5‑HT1B and 5‑HT1D receptors inhibits proliferation, clonogenicity and invasion of human pancreatic cancer cells. PLoS ONE. 2014;9:e105245.CrossRefPubMedPubMedCentral Gurbuz N, Ashour AA, Alpay SN, Ozpolat B. Down-regulation of 5‑HT1B and 5‑HT1D receptors inhibits proliferation, clonogenicity and invasion of human pancreatic cancer cells. PLoS ONE. 2014;9:e105245.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Pang Q, Liu C, Zhang JY, Qu K, Song SD, Liu SS, Xu XS. Serotonin in liver tumor: friend or foe? Hepatology. 2015;62:319.CrossRefPubMed Pang Q, Liu C, Zhang JY, Qu K, Song SD, Liu SS, Xu XS. Serotonin in liver tumor: friend or foe? Hepatology. 2015;62:319.CrossRefPubMed
35.
Zurück zum Zitat Padickakudy R, Pereyra D, Offensperger F, Jonas P, Oehlberger L, Schwarz C, Haegele S, et al. Bivalent role of intra-platelet serotonin in liver regeneration and tumor recurrence in humans. J Hepatol. 2017;67:1243–52.CrossRefPubMed Padickakudy R, Pereyra D, Offensperger F, Jonas P, Oehlberger L, Schwarz C, Haegele S, et al. Bivalent role of intra-platelet serotonin in liver regeneration and tumor recurrence in humans. J Hepatol. 2017;67:1243–52.CrossRefPubMed
36.
Zurück zum Zitat Aryal B, Shimizu T, Kadono J, Furoi A, Komokata T, Inoue M, Ikeda S, et al. A Switch in the Dynamics of Intra-Platelet VEGF-A from Cancer to the Later Phase of Liver Regeneration after Partial Hepatectomy in Humans. PLoS ONE. 2016;11:e150446.CrossRefPubMedPubMedCentral Aryal B, Shimizu T, Kadono J, Furoi A, Komokata T, Inoue M, Ikeda S, et al. A Switch in the Dynamics of Intra-Platelet VEGF-A from Cancer to the Later Phase of Liver Regeneration after Partial Hepatectomy in Humans. PLoS ONE. 2016;11:e150446.CrossRefPubMedPubMedCentral
Metadaten
Titel
Shaping the future of liver surgery
Implementation of experimental insights into liver regeneration
verfasst von
D. Pereyra
P. Starlinger, MD, PhD
Publikationsdatum
06.03.2018
Verlag
Springer Vienna
Erschienen in
European Surgery / Ausgabe 3/2018
Print ISSN: 1682-8631
Elektronische ISSN: 1682-4016
DOI
https://doi.org/10.1007/s10353-018-0515-3

Weitere Artikel der Ausgabe 3/2018

European Surgery 3/2018 Zur Ausgabe